Aurora Cannabis and Grow Group PLC renew their market access services agreement for medical cannabis in the UK
NYSE | TSX: ACB
EDMONTON, AB, May 20, 2021 / PRNewswire / – Aurora Germany GmbH, a subsidiary of Aurora Cannabis Inc. (the “Company” or “Dawn“) (NYSE: ACB) (TSX: ACB), the Canadian company that defines the future of cannabinoids around the world, and Grow Group PLC (” Grow “), a biopharmaceutical company focused on improving access to cannabis-based drugs in the UK (âUKâ), today announced the extension of their long-standing strategic relationship by signing a two-year Market Access Services Agreement for the United Kingdom. Aurora was one of the first companies to enter into a strategic relationship with Grow in August 2019 and since then both companies have become leaders in the rapidly growing medical cannabis market in the UK.
“We are delighted to extend our existing strategic relationship with Grow,” said Miguel Martin, CEO of Aurora Cannabis. âWe have worked successfully with Grow and their joint venture partner, IPS, since entering the UK market. The renewal of this agreement will help expand patient access by building on Grow’s work in educating physicians and raising awareness of medical cannabis options. Aurora is committed to providing access to high quality, pharmaceutical grade medical cannabis legally produced to meet the needs of the growing European medical cannabis market, made possible through our EU GMP facility, Aurora Nordic. “
âEverything we do is with the patient in mind. Meeting the needs of patients and expanding access to medical cannabis in the UK is at the heart of Grow’s strategy, âsaid Pierre van Weperen, Managing Director of Grow Group PLC, UK and Ireland. âProduct quality, a wide range of offerings and a strong supply chain are essential to serve the rapidly growing patient population in the UK. Partnering with companies like Aurora will continue to allow us to offer a portfolio of high quality flowers and extracts to the doctors and patients who will benefit from them. These products are making a difference for patients every day and we look forward to advancing market access with Aurora. “
Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Based at Edmonton, Alberta, Canada, Aurora is a global cannabis pioneer dedicated to helping people improve their lives. The company’s brand portfolio includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Pedanios, Whistler and Reliva CBD. Providing customers with innovative and high-quality cannabis products, Aurora’s brands continue to establish themselves as industry leaders in the medicine, performance, wellness and leisure markets, wherever they are launched. For more information, please visit our website at www.auroramj.com.
Aurora’s common shares trade on the TSX and NYSE under the symbol “ACB” and are included in the S & P / TSX Composite Index.
About Grow Group PLC
Grow Group PLC exists to unleash the medical potential of cannabis for those in need through three business units: Grow Pharma, Grow Trading and Grow Biotech. Grow Pharma works with the producers of the best cannabis medicines and helps them introduce their products to new markets like the UK and Ireland, creating long-term value for them and providing solutions to patients. The Grow Pharma team is also focused on supporting clinics and individual healthcare professionals and, through our partnership with IPS Specials Pharma, we are working with the best importer, distributor and pharmacy in the country to deliver the drug to patients. . Ultimately, all of Grow Group’s activities are aimed at improving patient access to cannabis-based medicines. Learn more about us on www.growgroupplc.com and follow us on LinkedIn www.linkedin.com/company/grow-grow-plc.
SOURCE Aurora Cannabis Inc.